injection and tail-tip-bleeding was performed from each animal at 20, 40, 60, 120, and 240 min after injection, sampling 2025 L of blood per time point as illustrated in (Fig
Epilepsia 38 (8), 950953
Disclosures: Stuart Forbes: Resolution Therapeutics: Founder, Resolution Therapeutics: Founder, Paul Brennan: Resolution Therapeutics: Independent Contractor, Takeda: Speaking and Teaching, Mark Macmillan: Nothing to Disclose, Thomas Manship: Nothing to Disclose, francesca moroni: Nothing to Disclose, Alison Glover: Nothing to Disclose, Debbie Troland: Nothing to Disclose, Iain MacPherson: Nothing to Disclose, Catriona Graham: Nothing to Disclose, Scott Semple: Nothing to Disclose, David Morris: Nothing to Disclose, Alasdair Fraser: Nothing to Disclose, Chloe Pass: Nothing to Disclose, Neil McGowan: Nothing to Disclose, Lynn Manson: Nothing to Disclose, Marc Leighton Turner: Nothing to Disclose, Neil Lachlan: Nothing to Disclose, John Dillon: Gilead: Speaking and Teaching, Abbvie: Speaking and Teaching, Alastair Kilpatrick: Nothing to Disclose, John Campbell: Resolution Therapeutics Ltd: Advisor, Resolution Therapeutics Ltd.: Stock privately held company, Jonathan Fallowfield: Stimuliver: Advisor, Ipsen: Advisor, Kynos Therapeutics: Advisor, Resolution Therapeutics: Consultant, River 2 Renal Corp.: Advisor, Global Clinical Trial Partners: Advisor, Guidepoint: Consultant, GlaxoSmithKline: Grant/Research Support, Genentech: Grant/Research Support, Intercept Pharmaceuticals: Grant/Research Support, Stuart Forbes: Resolution Therapeutics: Founder, Resolution Therapeutics: Founder 2649 PERFORMANCE OF THE CAGE-B AND SAGE-B SCORES FOR PREDICTION OF HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B PATIENTS WITH ADVANCED FIBROSIS Lesley Patmore 1 Lilian Yan Liang 2 Mai Kilany 3 Arno Furqium d'Almeida 4 Vincent Wong 5 Thomas Vanwolleghem 6 Pieter Honkoop 7 Hans Blokzijl 8 zgr Muhammet Koc 9 Harry Janssen 10 Matthijs Kramer 9 Joep de Bruijne 11 Apichat Kaewdech 12 Robert De Man 6 Bart Takkenberg 13 Grace Lai-Hung Wong 2 Jordan Feld 3 Milan Sonneveld 6 , 1 Erasmus MC, University of Rotterdam, 2 The Chinese University of Hong Kong, 3 Toronto General Hospital, 4 Antwerp University Hospital, 5 The Chinese University Hong Kong, 6 Erasmus University Medical Center, 7 Albert Schweitzer Hospital, 8 UMC Groningen, 9 Maastricht UMC+, 10 Erasmus MC, 11 UMC Utrecht, 12 Prince of Songkla University, 13 Amsterdam University Medical Centers, location AMC Background: Patients with chronic hepatitis B (CHB) treated with nucleo(s)tide analogues (NA) remain at risk for hepatocellular carcinoma (HCC)
This enhanced neutrophil recruitment was further confirmed by Ly6G immunostaining (Fig
Early intervention may be indicated for those showing rapid deterioration or high-risk features, while close monitoring may suffice for stable cases
